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INTRODUCTION
C y t o m e g a l o v i rus (CMV) disease continues to be a major
and life-threatening complication in recipients of blood and
bone marrow transplants (BMTs). CMV may cause deadly
interstitial pneumonitis, esophagitis, gastritis, colitis, hepati-
tis, fever, leukopenia, and a severe wasting syndrome [1-3].
The epidemiology of CMV infections in BMT recipients has
been described [1,4] in an attempt to identify patients most
at risk. Despite the discovery that the acyclic nucleoside gan-
ciclovir combined with intravenous immunoglobulin (IVIg)
is effective in treating CMV interstitial pneumonitis, the
m o rtality rate in infected patients continues to be as high as
30% to 50% [5,6]. Demonstration of the efficacy of both
acyclovir [7,8] and ganciclovir [9] in prophylaxis for patients
at high risk for CMV disease has led to mounting interest in
identifying the safest and most effective preventive therapy
in BMT patients. In allogeneic BMT (alloBMT) re c i p i e n t s ,
attempts to prevent disease using ganciclovir have used 1 of 2
strategies [10], prophylactic administration to all CMV-
s e ropositive patients [11,12] or early treatment of patients
deemed to be at high risk based on evidence of CMV activa-
tion in surveillance tests (cultures, sero l o g y, antigen detec-
tion) of blood and other body fluids [9,13]. Routine adminis-
tration of ganciclovir to all CMV- s e ropositive patients leads
to unnecessary therapy, with the potential for drug toxicity
[10-12] including profound neutropenia, for 30% to 65% of
all seropositive patients who would never develop CMV dis-
ease. This strategy generates added costs of ganciclovir ther-
apy plus those related to management of any subsequent
complications (hematopoietic growth factors, antibiotics, and
additional hospitalization). 
A l t e rn a t i v e l y, early treatment of CMV infection is highly
dependent on the reliability and sensitivity of the surv e i l-
lance test used to detect early CMV activation. Initial studies
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using conventional and centrifugation (shell vial) surv e i l l a n c e
c u l t u res of throat, blood, and urine re p o rted that 12% to
35% of patients developed CMV disease before or concomi-
tant with the first positive surveillance cultures [9,10,13]. This
has led to interest in faster and more sensitive tests for detect-
ing early CMV activation, including immunohistochemical
detection of the presence of the early viral matrix stru c t u r a l
p rotein, pp65, in leukocytes using monoclonal antibodies
(CMV antigenemia) [14,15]. This assay has been shown to be
v e ry sensitive and specific for CMV infection [16-18], giving
a positive result a median of 10 days before surveillance cul-
t u res [16]. Although the effectiveness of early treatment using
this assay for surveillance in allogeneic transplantation
patients has been described [16,18], its optimal clinical utility
in a broad transplantation population including autologous
BMT (autoBMT) recipients remains unclear. To assess the
risk factors for and clinical outcomes of CMV antigenemia as
d e t e rmined by the pp65 antigen assay in BMT recipients, we
evaluated the CMV antigen test results and clinical outcomes
of all consecutive patients transplanted at the University of
Minnesota over a 7-month period. 
MATERIALS AND METHODS
Pa t i e n t s
Data re g a rding pretransplantion characteristics, type of
transplant, posttransplantion complications, and survival were
collected prospectively by the Biostatistics Support Group at
the University of Minnesota using standardized methods. To
verify completeness of CMV surveillance, one of us (M.A.W. )
tabulated results of all CMV studies (sero l o g y, antigenemia,
c u l t u res) on all BMT recipients from the computerized
re c o rds of the hospital virology laboratory. Details of CMV
therapy and clinical outcomes were obtained from a review of
patients’ medical re c o rds. We reviewed consecutive trans-
plantations from November 1, 1996, to May 31, 1997, at the
University of Minnesota. Follow-up continued thro u g h
M a rch 31, 1998. All patients had CMV serology tested within
4 weeks before transplantation. Donor CMV serology was
tested before blood stem cell or bone marrow harvest. All
patients were first-time BMT re c i p i e n t s .
CMV Pr o p hy l a x i s
C M V- s e ronegative autoBMT patients and CMV-
s e ronegative alloBMT patients with a seronegative donor
received only CMV-safe (CMV-negative or leukocyte-
depleted) blood products and no chemoprophylaxis [19].
C M V- s e ropositive autoBMT patients and CMV- s e ro p o s i-
tive alloBMT patients with a seropositive donor re c e i v e d
acyclovir 10 mg/kg IV 3 times a day or, when feasible, 800 mg
(18 mg/kg for pediatric patients) orally 5 times a day from
day –4 to day 30. The oral therapy was continued until day
100. Eighteen CMV- s e ropositive alloBMT patients, irre-
spective of donor CMV status, participated in a continuing
prospective randomized trial comparing high-dose acyclovir
to ganciclovir prophylaxis for CMV. The study pro t o c o l
called for administration of ganciclovir 5 mg/kg IV every
12 hours from day –7 to day –2, then acyclovir 10 mg/kg
e v e ry 8 hours from day –1 until randomization at engraft-
ment. Patients randomized to ganciclovir received 5 mg/kg
IV once every weekday (Monday through Friday) until day
100. Acyclovir prophylaxis entailed continuing with 800 mg
(adults) or 18 mg/kg (children) orally 5 times a day until day
100. All patients on the trial also received IVIg 500 mg/kg
on days –6, 0, 7, 21, 35, 55, 76, and 98. The trial was
approved by the Institutional Review Board of the Univer-
sity of Minnesota, and all enrolled patients or their legal
guardians gave written informed consent. CMV-seropositive
alloBMT patients who did not participate in the trial
received acyclovir 10 mg/kg IV 3 times a day or, when feasi-
ble, 800 mg (18 mg/kg for pediatric patients) orally 5 times
a day from day –4 to day 30 and continued with oral acy-
clovir from day 31 to day 100. They also received IVIg
500 mg/kg on days –6, 7, 21, and 35. 
C M V- s e ronegative patients with CMV- s e ro n e g a t i v e
donors who were seropositive for herpes simplex virus were
t reated with acyclovir 400 mg (9 mg/kg for pediatric
patients) orally or 5 mg/kg IV twice a day until engraftment
and resolution of oropharyngeal mucositis. 
CMV Therapy
All patients with evidence of CMV disease were treated
with an induction dose of ganciclovir 5 mg/kg IV twice a
day for 14 days, followed by a maintenance dose of 5 mg/kg
IV every weekday for 6 weeks and IVIg 500 mg/kg on alter-
nate days for 2 weeks, then twice a week for another 4 weeks.
Patients who developed evidence of recurrent CMV disease
during the maintenance period or whose ganciclovir therapy
was interrupted for any reason were reinduced with twice-
a -day ganciclovir. Patients with antigenemia (2 or more
p o sitive cells per 50,000) in the absence of organ disease
were eligible to receive ganciclovir in the same schedule and
for the same duration, but without IVIg. Foscarnet was
given to patients whose antigenemia did not resolve with
ganciclovir therapy or in whom myelosuppression prevented
ganciclovir administration. 
CMV Surv e i l l a n c e
Once a week, starting on day –7, CMV antigenemia
assay was done using a commercial kit (CMV-Vue; Incstar,
S t i l l w a t e r, MN) according to the manufacture r ’s instru c-
tions, as described [17]. Patients with <2 positive cells per
50,000 or insufficient numbers of leukocytes for the assay
had their test repeated within 1 week. Conventional and
shell vial cultures of blood, bro n c h o - a l v eolar lavage fluid,
and biopsied tissue for isolation of CMV were performed as
appropriate, using standard methods as described [17]. 
D e f i n i t i o n s
CMV disease. C u l t u re of CMV (by conventional or shell-
vial technique) from visceral tissue samples; from broncho-
alveolar lavage fluid in the presence of fever, unexplained
hypoxia, or new or changing pulmonary infiltrates; or
pathologic changes of CMV in biopsy tissue.
CMV antigenemia. One or more positive cells per 50,000 (or
fewer) leukocytes examined.
CMV infection. Culture of CMV from any site. 
Statistical Anal y s i s
The incidence of CMV antigenemia was measured at
100 days posttransplantation. Estimates were calculated by
Kaplan-Meier methods, and 95% confidence limits were
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d e t e rmined from the standard errors. Diff e rences between
groups were tested using Mantel-Cox log rank test of signif-
icance. Multiple re g ression analysis was perf o rmed using
Cox pro p o rtional hazards re g ression models. Risk factors
w e re evaluated among all patients as well as among the
s u bgroup of allogeneic patients. Regression models for the
allogeneic patients were stratified by donor type. Acute
graft-versus-host disease (GVHD) was treated as a time-
dependent covariate. Other risk factors evaluated in the
analysis included age, sex, underlying diagnosis, type of
transplant, recipient and donor CMV serostatus, CMV pro-
phylaxis, GVHD prophylaxis, and conditioning regimen.
RESULTS
Pa t i e n t s
Table 1 summarizes the demographic characteristics of
the 118 consecutive BMT recipients studied. Seventy-eight
patients (66%) received alloBMT, 6 of them cord blood
transplants, and 40 patients (34%) received autoBMT. Pre-
transplantation, 62 patients (53%) were CMV- s e ro p o s i t i v e .
Of 78 donors, 34 (44%) were CMV-seropositive. Sixty-one
percent of all patients received prophylaxis with either acy-
clovir (50%) or ganciclovir (11%), and 39% re q u i red no
prophylactic therapy; 76% of all patients received total-body
i rradiation as part of their pretransplantation conditioning
regimen. Acute or chronic leukemia was diagnosed in 48%
of patients, and 82% overall had malignant disease.
Risk Factors for CMV Antig e n e m i a
Of 118 patients in the cohort, 43 (36%) developed
CMV antigenemia at some point during follow-up. The
median onset of antigenemia was day 26 post-BMT (range,
–6 to 209 days). Of the 43 antigen-positive patients, 39
(91%) first developed antigenemia between days –6 and 100.
We evaluated potential risk factors for CMV antigenemia;
the results are shown in Table 2. Pretransplantation CMV
serology and the type of transplant were the most important
factors associated with antigenemia. Patient age at trans-
plantation, sex, and underlying disease (malignant versus
nonmalignant) were not associated with differing risk for
antigenemia. As shown in Figure 1A, the incidence of CMV
antigenemia within the first 100 days post-BMT was 50%,
48%, and 15% for recipients of related donor (RD), unre-
lated donor (URD), and autoBMT, respectively (P = .01).
The probability of CMV antigenemia was significantly
higher (P < .01) in seropositive recipients than in seronega-
tive recipients, 51% versus 19% (Figure 1B and 1C). 
Multiple re g ression analysis confirmed that alloBMT
and pre-BMT positive CMV serology were independent
significant risk factors for CMV antigenemia within the
first 100 days post-BMT (Table 2). Compared with
autoBMT recipients, recipients of RD and URD BMT had
2.4- and 4.4-fold the risk of CMV antigenemia, re s p e c-
tively (P < .01). CMV- s e ropositive patients had 3.8-fold
the risk of seronegative patients (P < .01). In evaluating the
risk factors for antigenemia among alloBMT patients, the
development of GVHD was independently associated with
a 2.2-fold increased risk of antigenemia (P = .03). In
s e ronegative recipients, positive donor CMV serology led
to a modest, but not significantly gre a t e r, risk of antigene-
mia (Figure 1C and Table 2). Neither CMV pro p h y l a c t i c
regimen (for seropositive patients) nor GVHD pro p h y l a x i s
using T-cell depletion were significant risk factors for
developing antigenemia. 
CMV Disease
Eleven of 118 patients (9%) developed CMV disease, a
median of 101 days post-BMT (range, 28-283 days) (Table 3).
CMV disease occurred in 10 (23%) of the 43 patients who
developed antigenemia and 1 (1%) of 75 patients who did not
( Table 4). All 11 patients who developed disease were CMV
s e ropositive alloBMT recipients (Table 3). The median inter-
val between initial antigenemia and development of CMV
disease was 45 days (range, 1-222 days). Eight patients devel-
oped pneumonitis, and 2 developed gastro i ntestinal disease.
Table 1. Pretransplantation Characteristics*
Number of patients 118
Median age in years (range) 36 (0.3-62)
Sex
Male 62 (53)
Female 56 (47)
Underlying disease
Acute leukemia 36 (31)
Chronic myelogenous leukemia 20 (17)
Other malignancy 43 (36)
Nonmalignant disease 19 (16)
Pretransplantation CMV serology
Autologous
Negative 21 (18)
Positive 19 (16)
Allogeneic (recipient/donor)
Negative/negative 25 (21)
Negative/positive 10 (8)
Positive/negative 19 (16)
Positive/positive 24 (20)
CMV prophylaxis
Acyclovir 59 (50)
Ganciclovir 13 (11)
None 46 (39)
Type of transplant
Related 34 (29)
Unrelated 44 (37)
Autologous 40 (34)
Conditioning regimen
Cyclophosphamide/total-body irradiation 67 (57)
Multidrug chemotherapy/total-body irradiation 23 (19)
Multidrug chemotherapy/no radiation 28 (24)
GVHD prophylaxis †
Methotrexate + cyclosporine 44 (56)
T-cell depletion + cyclosporine 26 (33)
Cyclosporine alone 8 (10)
Maximum GVHD grade †
None 36 (46)
Grade I 11 (14)
Grade II 27 (35)
Grade III 4 (5)
Grade IV 0
*Data are n (%) unless otherwise indicated. GVHD indicates graft-versus-
host disease.
†Allogeneic recipients only (n = 78).
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One had central nervous system (CNS) infection first
detected at autopsy. The attack rate for CMV disease in
antigenemic patients diff e red by type of transplant, with
10 of 37 antigenemic alloBMT patients (27%) and 0 of
6 autoBMT patients developing CMV disease. 
Nine patients had detectable antigenemia more than 1
week preceding their diagnosis of CMV disease (Table 3).
Seven of these patients had persistent antigenemia before the
onset of CMV disease. Antigenemia spontaneously re s o l v e d
b e f o re onset of disease in 2 patients, 1 of whom received no
antiviral therapy for an antigen level of 12 cells per 50,000 and
developed CMV pneumonitis 117 days later. The 1 antigen-
negative patient who developed disease had remained persis-
tently leukopenic until he developed pneumonitis. 
Six of 11 patients developed late CMV disease (occur-
ring more than 100 days posttransplantation). Two of
these 6 patients were recipients of a T-cell–depleted graft,
c o m p a red with 1 of 5 patients with early CMV disease
( o c c u rring before day 100). All 6 patients with late disease
had prior significant acute GVHD and had re c e i v e d
extended cort i c o s t e roid therapy. Four of them also devel-
oped chronic GVHD, 3 before the occurrence of CMV dis-
ease. Only 2 of the 5 patients with early CMV disease
required steroid therapy for acute GVHD, and 1 developed
acute GVHD after the onset of CMV disease. 
Table 4 contrasts the demographic characteristics of
3 g roups of patients: antigen-negative, antigen-positive
w i t hout CMV disease, and antigen-positive with CMV
Table 2. Risk Factors for CMV Antigenemia Before Day 100 Posttransplantation*
Number of patients Multivariate
Antigenemia Incidence Univariate analysis † regression analysis ‡
Risk factor At risk post-BMT [% (95% CI)] † P RR ‡ 95% CI ‡ P
Cohort 118 39 36 (27-45)
Age at transplantation (years) NS
<18 44 17 42 (27-59)
>18 74 22 33 (22-44)
Sex NS
Male 62 23 41 (28-54)
Female 56 16 31 (19-43)
Underlying diagnosis NS
Malignant disease 19 8 45 (22-68)
Nonmalignant disease 99 31 34 (24-44)
Type of transplant .01
Autologous 40 6 15 (4-25) 1.0 — —
Related donor 34 13 50 (30-70) 2.4 0.9-6.5 .07
Unrelated donor 44 20 48 (33-63) 4.4 1.7-11.0 <.01
Recipient CMV serostatus <.01
Negative 56 10 19 (8-30) 1.0 — —
Positive 62 29 51 (38-64) 3.8 1.8-8.1 <.01
Recipient/donor serostatus § <.01
Negative/negative 25 4 18 (2-34)
Negative/positive 10 4 44 (11-77)
Positive/negative 19 13 76 (56-96)
Positive/positive 24 12 57 (35-79)
Recipient negative 1.0 — —
Recipient positive 4.2 1.8-9.9 <.01
Stem cell source § i
Peripheral blood 15 6 58 (27-89)
Marrow 57 24 46 (32-60) .75
CMV prophylaxis §¶ NS
Acyclovir 30 17 67 (48-86)
Ganciclovir 13 8 64 (37-91)
T-cell depletion § NS
No 52 21 47 (32-62)
Yes 26 12 51 (31-71)
Grade II-IV acute GVHD § .03
No 56 23 42 (26-54) 1.0 — —
Yes 22 10 67 (33-84) 2.2 1.0-4.7 .04
*BMT indicates bone marrow transplantation; GVHD, graft-versus-host disease; NS, not significant. 
†Kaplan-Meier univariate analysis of the time to first antigenemia after BMT.
‡Cox multiple regression model including factors identified as important in univariate analysis. Acute GVHD was considered as a time-dependent covariate.
§AlloBMT recipients only. 
iExcludes 6 recipients of cord blood transplant.
¶CMV-seropositive allogeneic BMT recipients only. 
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d i sease. Although age and underlying disease were not dif-
f e rent, CMV antigenemia and disease were notably less fre-
quent in autoBMT recipients. The few cases of CMV disease
o b s e rved (n = 11) preclude meaningful statistical analysis of
characteristics that might differ between the groups.
C M V-associated mortality was 40%, 0%, and 1.3% for
patients with antigenemia and CMV disease, antigenemia
without CMV disease, and no antigenemia, re s p e c t i v e l y. As
shown in Figure 1D, 12-month overall survival was similar in
patients with and without CMV antigenemia (P = .42). The
1-year survival rate for patients who developed antigenemia
and disease was 57% (95% confidence interval [CI] 25-89),
c o m p a red with 82% (CI 69-95) for those with antigenemia
without disease and 63% for patients without antigenemia.
CMV Therapy
Eighteen patients (all CMV seropositive) received treat-
ment for CMV antigenemia or disease. All but 1 of them
w e re CMV antigen–positive and received treatment initi-
ated a median of 14 days (range, 0-126 days) after the initial
positive antigen test. Only 1 patient, CMV seropositive, was
an autoBMT recipient. Seventeen patients were treated with
ganciclovir and 1 with acyclovir alone because of profound
n e u t ropenia. Protocol-specific therapy was scheduled to
continue for 56 days, and the median duration of antiviral
therapy was 61 days (range, 15-202 days). 
After initiation of therapy, the median time to clearance
of antigenemia was 22 days (range, 2-178 days). Thre e
patients had not cleared their antigenemia by the time of
their last documented test. Five patients required more than
1 course of therapy because of recurrent or persistent anti-
genemia. Four of these patients eventually received foscar-
net because of unremitting antigenemia, clinically inter-
preted as evidence of resistance to ganciclovir. Two of these
developed CMV disease: 1 had esophagitis, the other had
CNS infection detected at autopsy. 
Natural History of Untreated CMV Antig e n e m i a
Twenty-six patients (21 alloBMT; 5 autoBMT) developed
antigenemia but received no antiviral treatment during fol-
low-up. Twenty of these 26 patients had a peak antigen level
of 1 cell per 50,000 and so were not eligible for treatment. Of
the other 6 patients (4 alloBMT; 5 seropositive) who had a
peak antigen level >1 cell per 50,000, 5 had a peak of 2 cells
per 50,000 and 1 a single measure of 4 positive cells. Two of
these patients had no subsequent testing. Fourteen of the 26
patients were CMV seropositive (11 alloBMT) and thus were
at higher risk for viral reactivation. The median onset of anti-
A B
C D
Figure 1. Incidence of CMV antigenemia post–bone marrow transplantation (BMT) analyzed by risk factor. A: Type of transplant. Auto indicates autologous;
RD, related donor; URD, unrelated donor. B: Pretransplantation recipient CMV serology. C: Recipient/donor CMV serology pre-BMT. D: Impact of CMV anti-
genemia on survival post-BMT.
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genemia was 28 days post-BMT (range, –6 to 209 days), the
median initial antigen level was 1 cell per 50,000 (range, 1-4),
and the median peak level was 1 cell per 50,000 (range, 1-4).
The median duration to spontaneous clearance of antigene-
mia was 7 days (range, 1-104 days). One patient did not clear
his low-level antigenemia through 11 subsequent tests. None
of the 26 untreated antigenemic patients showed any sign of
CMV disease through complete clinical follow-up.
Consistency of Antigenemia Surveillance and Quality
of Te s t i n g
The pro p o rtion of surviving patients who were tested
weekly diff e red markedly between autoBMT and alloBMT
recipients. Greater than 60% of all patients had 1 or more
antigen assay each week through the first 8 weeks. However,
w h e reas more than 60% of RD and URD patients were tested
weekly through 9 and 13 weeks post-BMT, re s p e c t i v e l y, the
f requency of surveillance for autoBMT recipients was lower.
As a consequence of the autoBMT patients’ more rapid re c o v-
e ry and release from closer surveillance at the transplant cen-
t e r, 60% or more were tested for only the first 4 weeks.
Of a total of 1676 CMV antigen tests perf o rmed in the
c o h o rt, 293 (17%) were re p o rted to have an insufficient quan-
tity of cells (<50,000 per slide) to give a reliable quantitative
result (Table 4). During post-BMT weeks 1 and 2, 50% and
45% of samples, re s p e c t i v e l y, had insufficient numbers of cells.
In all other weeks, >75% of samples were adequate for quanti-
tative assay. One patient developed pneumonitis after 5 nega-
tive tests, all with insufficient quantity of cells; on the day of
pneumonitis diagnosis, a shell vial culture of bro n c h o - a l v e o l a r
lavage fluid isolated CMV. The frequency of adequate samples
(those with sufficient leukocytes for examination) was similar
in those with no antigenemia versus those with antigenemia,
with or without CMV disease (Table 4), suggesting a similar
intensity of surveillance in the 3 gro u p s .
DISCUSSION
CMV antigenemia and disease was a major problem in
this cohort of 118 consecutive BMT patients. Of the whole
g roup, 36% developed antigenemia and 9% developed org a n
disease. Previous studies that evaluated the risk for CMV dis-
ease by antigen surveillance excluded the lower-risk gro u p s
(autoBMT and seronegative alloBMT), yet we observed a
15% incidence of antigenemia in autoBMT and a 19% inci-
dence in seronegative patients. Although the incidence of
CMV pneumonitis is re p o rtedly much lower in autoBMT
recipients (2%-7%) [22,23], their fatality rate may be as high
as in alloBMT patients, emphasizing the importance of con-
tinued surveillance and effective prophylaxis to limit their
disease attack rate. It is interesting that 1 of 6 sero p o s i t i v e
autoBMT patients in our study who developed antigenemia
re q u i red therapy with ganciclovir for high-level antigenemia. 
Clinical use of a defined level of antigenemia as a trigger
for preemptive antiviral therapy has been re p o rted by
Boeckh et al. [20], who used a level of 3 positive cells per
50,000, but only in seropositive alloBMT recipients. This
level of antigenemia as an indication for therapy has been
i n t e r p reted as possibly limiting the utility of the pre e m p t i v e
therapy strategy, potentially allowing more patients to
develop disease before the threshold for treatment is
reached. We used a lower level of antigenemia (2 positive
cells per 50,000) as a possible indicator of the need for ther-
a p y. However, of 20 untreated patients with low-level anti-
genemia (<2 cells per 50,000), none developed CMV disease.
As with previous reports of CMV infection, the recipi-
e n t ’s pre-BMT serology and type of transplant were the
strongest indicators of the risk for CMV antigenemia. Mod-
erate to severe GVHD was an added and significant factor
predictive of antigenemia. Notably, of the 15% of autoBMT
recipients who developed antigenemia, none developed
CMV disease, although 1 re q u i red treatment with ganci-
Table 3. Patients With CMV Disease*
Patient Number
1 2 3 4 5 6 7 8 9 10 11 Median
Diagnosis MM ALL RAEB CML CML ML AML Man CLL AML ALL
Type of transplant RD URD RD RD RD URD URD URD RD RD RD
CMV status pre-BMT +/+ +/– +/– +/+ +/– +/+ +/+ +/– +/– +/– +/+
(recipient/donor)
CMV prophylaxis G A G A A A A G A A A
Days from BMT to 183 030 042 061 023 025 –3 042 20 27 — 029
initial antigenemia
Antigen level †
Initial 008 001 001 001 01 002 01 002 01 01 00 001
Peak 008 011 006 012 01 090 03 018 04 30 00 008
CMV disease P P G I P P E P P P G I P
Days to CMV disease
From BMT 184 252 101 283 51 207 28 107 41 38 36 101
From first antigenemia 001 222 059 124 28 180 31 065 21 11 — 045
Days from first 001 000 002 126 28 002 41 010 21 18 — 014
antigenemia to 
antiviral therapy
*A indicates acyclovir; ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; E, encephalitis; G, ganci-
clovir; GI, gastrointestinal tract infection; ML, metachromatic leukodystrophy; MM, multiple myeloma; P, pneumonitis; RAEB, refractory anemia with excess
blasts; RD, related donor; URD, unrelated donor. 
†Number of positive cells per 50,000 leukocytes. 
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clovir for rising antigenemia. The low frequency of antigen-
emia in the autoBMT patients may in part reflect the lower
proportion of these patients tested beyond the 4th week of
t r a n s p l a n t ation. However, their complete clinical follow-up
identified no subsequent cases of CMV disease, consistent
with their observed lower risk of early posttransplantation
a n t i g e n e m i a .
All seropositive alloBMT patients in our study re c e i v e d
either acyclovir or ganciclovir for prophylaxis with no
a p p a rent diff e rence in risk of CMV antigenemia. Although
the number of patients in both groups is relatively small,
the striking similarity in incidence rates and confidence
i n t e rvals suggests the veracity of this finding. A specific a l l y
designed, randomized prospective study is needed to cor-
roborate this observation. Of seropositive alloBMT re c i p i-
ents, 63% developed antigenemia in our study, compare d
with a re p o rted 41% and 79% antigenemia in similar
patients randomized to receive ganciclovir prophylaxis and
placebo, respectively [20]. 
Eleven patients, all CMV- s e ropositive alloBMT re c i p i-
ents, developed CMV disease. All but 1 of these patients
developed antigenemia before the onset of disease. Of the
75 patients who were persistently antigen negative, only 1,
with prolonged leukopenia, developed CMV disease. The
assay for leukocyte expressed antigenemia has limited sensi-
tivity to identify patients at risk for CMV disease during the
early leukopenic period. Of note is that 17% of all our sam-
ples had an inadequate number of leukocytes to provide re l i-
able quantitative results, and 31 of 43 patients (72%) had their
initial positive antigen test preceded by multiple tests with an
i n s u fficient number of leukocytes for a valid assay. Cell-fre e
assays (polymerase chain reaction for plasma viral DNA) may
o v e rcome this assay insensitivity during leukopenia, although
p rospectively generated data are yet to be re p o rt e d .
The attack rate for CMV disease was 23% (10 of 43) in
antigen-positive patients and 27% (10 of 37) in the subset
of antigen-positive alloBMT patients. Six of 11 patients
developed CMV disease after day 100. In both the inci-
dence and timing of CMV disease, these findings are simi-
lar to re p o rts from Seattle in which 15 of 18 patients who
developed CMV disease after early ganciclovir pro p h y l a x i s
did so after day 100, whereas only 7 of 23 patients not
receiving prophylaxis acquired late CMV disease [20]. It
may be surmised that effective prophylactic therapy causes
a delay in CMV-specific immunologic re c o v e ry posttrans-
plantation, permitting late-onset CMV disease after discon-
tinuation of suppressive antiviral therapy. 
Another putative risk factor for delayed-onset CMV dis-
ease may be suppression of cell-mediated immunity, such as
might occur following steroid therapy for acute or chronic
GVHD. Of note is the fact that all 6 patients who developed
late CMV disease had received weeks of steroid therapy
for clinically significant GVHD compared with only 2 of
5 patients with early CMV disease.
In conclusion, CMV antigenemia occurs frequently in
s e ropositive pat ients despite prophylaxis with either
Figure 2. Surveillance for CMV antigenemia after bone marrow transplantation. AUTO indicates autologous; RD, related donor; UD, unrelated donor.
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a c yclovir or ganciclovir. CMV- s e ropositive alloBMT
recipients have the highest risk of developing antigenemia.
Antigenemia is less common but still apparent in a sizable
fraction of autologous and CMV- s e ronegative BMT
patients. Leukopenic patients may develop significant dise a s e
without prior low-grade antigenemia. CMV- s e ro n e g a t i v e
autoBMT patients may re q u i re less frequent monitoring
for CMV in view of their low risk for CMV antigenemia
and disease.
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